Premium
Immunotherapy of melanoma by GPI‐anchored IL‐21 tumour vaccine involves down‐regulating regulatory T cells in mouse model
Author(s) -
Wang J.,
Zhao F.,
Dou J.,
He X. F.,
Chu L.,
Cao M.,
Liu C.,
Li Y.,
Gu N.
Publication year - 2011
Publication title -
international journal of immunogenetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.41
H-Index - 47
eISSN - 1744-313X
pISSN - 1744-3121
DOI - 10.1111/j.1744-313x.2010.00962.x
Subject(s) - foxp3 , melanoma , immunotherapy , immune system , immunology , cancer research , il 2 receptor , biology , metastatic melanoma , t cell , medicine
Summary In this study, we developed a tumour cell vaccine expressing a glycosylphosphatidylinositol (GPI)‐anchored IL‐21 to test the effect of immunotherapy of melanoma in mouse model. The results indicated that the tumour vaccine was functional, exhibiting delayed tumour growth and prolonging longevity of tumour bearing mice. The immunotherapeutic effect was associated with decreasing the numbers of CD4 + CD25 + Foxp3 + Treg (Tregs) cells, increasing IFN‐γ level and promoting lymphocyte‐infiltration in tumour tissues. Overall, our data demonstrate that the GPI‐anchored IL‐21 tumour vaccine regulates immune responses at least in part by down‐regulating Tregs and reveals enhanced efficacy of tumour vaccine therapy of melanoma.